SHPH Company Profile and Key Details

SHPH has shown mixed momentum, gaining 49.65% over the past week and -41.05% over the past quarter, though year-to-date performance is up 18.89%. Short-term trend indicators are bullishly aligned (SMA20 -21.1%, SMA50 -34.29%, SMA200 -64.52%). The stock’s 14-day RSI is 37.12 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.21% below its high and over 9.0% above its low. Average 10-day trading volume of 5.96 million shares is significantly above the 3-month average of 804.86 thousand, indicating heightened recent market interest.

Shuttle Pharmaceuticals Holdings, Inc. generated EPS of -$21.74 over the past year. Five-year average earnings growth is -55.05%.

Shuttle Pharmaceuticals Holdings, Inc. has 1.07 million shares outstanding. The public float is 987.08 thousand shares, elevated short interest at 4.57% of float. This equals 19.82 thousand shares. The short ratio is 0.11 days. Institutional investors hold 36.8% of the float. Insiders own 8.25%. Brown Milton holds 1.09 million shares, Dritschilo Anatoly has 1.09 million shares and Jung Mira has 1.07 million shares.

Shuttle Pharmaceuticals Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.62. This means the shares are trading above this model’s fair value.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) closed at $4.02 USD, gaining $0.24 (6.35%) from the previous close of $3.78. The stock is currently mid-range between its 52-week high and low $3.16 and $55.90. With a market capitalization of about $2.35 million, Shuttle Pharmaceuticals Holdings, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.22). Key stats such as the average daily volume over the past year has been around 829.50 thousand shares, trading with heavier-than-usual volume. Headquartered in Gaithersburg, MD, Shuttle Pharmaceuticals Holdings, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Christopher Robert Cooper, the company employs approximately 9 people and listed since August 31, 2022. Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy.

Shuttle Pharmaceuticals Holdings, Inc. trades at a P/E ratio of -0.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.59 suggesting the stock is closer to book value. The P/FCF stands at -0.25, also above market averages.

Our AI price prediction model suggests that Shuttle Pharmaceuticals Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -31.34%, with price expected at $2.76 by July 10, 2026, within a range of $2.49 to $3.03 3-Month Outlook: Projected rise of 23.38%, reaching $4.96 by September 24, 2026, with a range of $2.87 to $7.20. 1-Year Outlook: Projected loss of -96.02%, with price at $0.16 by June 25, 2027, within a range of $0.00 to $19.47.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) shares are up 18.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Shuttle Pharmaceuticals Holdings, Inc. trading at a premium to the broader market with a P/E of -0.07. Our AI forecast model points to short-term weakness (-31.34% over two weeks), a medium-term rise (23.38% over three months), and a longer-term loss (-96.02% over one year), with expected trading ranges indicating moderate volatility.